PR Newswire
LAS VEGAS, March 2, 2026
LAS VEGAS, March 2, 2026 /PRNewswire/ — The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth.
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current treatment practices, biliary tract cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Biliary Tract Cancer Market Summary
- The market size for biliary tract cancer was found to be USD 1.1 billion in the 7MM in 2024.
- The United States accounted for the largest biliary tract cancer treatment market size, approximately 60% of the total market size in the 7MM in 2024, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- In 2024, chemotherapy regimens continued to dominate the BTC market by therapy, accounting for ~70% of the market.
- In 2024, the total number of BTC incident cases across the 7MM was approximately 65,000, and this burden is projected to increase over the forecast period.
- Leading biliary tract cancer companies, such as TransThera Sciences (HKG: 2617), AstraZeneca (LON: AZN), J-Pharma, OHARA Pharmaceutical (TYO: 5218), Compass Therapeutics (NASDAQ: CMPX), Merck (NYSE: MRK), Eisai (TYO: 4523), Seagen (NASDAQ: SGEN), Pfizer (NYSE: PFE), Bold Therapeutics (NASDAQ: BOLD), Senhwa Biosciences, Virogin Biotech, Replimune (NASDAQ: REPL), Bayer (ETR: BAYN), RedHill Biopharma (NASDAQ: RDHL), Relay Therapeutics (NASDAQ: RLAY), Elevar Therapeutics, Eli Lilly (NYSE: LLY), Cogent Biosciences (Cogent Biosciences), Tanabe Pharma America (TYO: 4508), and others, are developing new biliary tract cancer treatment drugs that can be available in the biliary tract cancer market in the coming years.
- The promising biliary tract cancer therapies in clinical trials include Tinengotinib, Rilvegostomig, Nanvuranlat (JPH203), Tovecimig (CTX-009), Lenvatinib mesylate (LENVIMA), Tucatinib (TUKYSA), BOLD-100, Silmitasertib (CX-4945), VG161, RP3-003, Sevabertinib (BAY 2927088), Opaganib (ABC294640), Lirafugratinib (RLY-4008), Olomorasib (LY3537982), CGT4859, MT-4561, and others.
- According to DelveInsight’s analysis, by 2034, among therapies, the highest revenue is expected to be generated by chemotherapy, followed by durvalumab (IMFINZI) and tovecimig in the 7MM.
Discover the biliary tract cancer market share by therapy type @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Biliary Tract Cancer Market
- Rising BTC Incidence and Aging Populations: The global incidence of biliary tract cancers, including cholangiocarcinoma and gallbladder cancer, is increasing. The US accounted for approximately 19K biliary tract cancer cases in 2024, which are further expected to increase by 2034. This trend is attributed to factors such as aging populations, the rising prevalence of chronic liver diseases (like cirrhosis and hepatitis), and certain parasitic infections. The aging global population and environmental factors like obesity further contribute to the rise in diagnosed cases.
- Advancements in Imaging for Cholangiocarcinoma: Improving imaging techniques, such as magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), and positron emission tomography (PET), can enhance the accuracy of diagnosis, staging, and monitoring of cholangiocarcinoma, facilitating more tailored treatment approaches.
- Potential of FGFR2 Inhibitors: FGFR2 inhibitors such as pemigatinib and futibatinib have been effective in patients with FGFR2 alterations; however, resistance due to secondary mutations remains a challenge.
- Launch of Emerging Biliary Tract Cancer Drugs: The dynamics of the BTC market are expected to change in the coming years due to the launch of emerging therapies such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), Tucatinib (TUKYSA) (Seagen/Pfizer), BOLD-100 (Bold Therapeutics), Silmitasertib (CX-4945) (Senhwa Biosciences), VG161 (Virogin Biotech), RP3-003 (Replimune), Sevabertinib (BAY 2927088) (Bayer), Opaganib (ABC294640) (RedHill Biopharma), Lirafugratinib (RLY-4008) (Relay Therapeutics/Elevar Therapeutics), Olomorasib (LY3537982) (Eli Lilly), CGT4859 (Cogent Biosciences), MT-4561 (Tanabe Pharma America), and others.
Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, said that in recent years, the integration of precision oncology has significantly reshaped the treatment landscape for advanced BTC. Targeted therapies directed against FGFR2 fusions, IDH1 mutations, BRAF V600E mutations, NTRK fusions, HER2 amplifications, and microsatellite instability (MSI-H) have enabled more personalized treatment approaches. These advances have been particularly impactful in intrahepatic cholangiocarcinoma, where the prevalence of actionable genomic alterations is higher, thereby shifting from empiric chemotherapy to biomarker-driven treatment paradigms for selected patient populations.
Biliary Tract Cancer Market Analysis
- Therapeutic management of BTC is determined by disease stage and anatomical subtype.
- Early-stage BTC can be curable with surgical resection; however, most patients are ineligible due to late diagnosis.
- High rates of post-surgical recurrence highlight the limited durability of surgery alone and the need for adjuvant systemic therapy.
- In unresectable or metastatic BTC, first-line chemotherapy remains the standard of care but provides only modest and short-lived benefit.
- Rapid disease progression in advanced BTC leads to high attrition and limits access to subsequent lines of therapy.
- Molecular profiling has driven a major shift in the treatment landscape, particularly in iCCA, enabling the identification of actionable genomic alterations.
- Targeted therapies for molecularly selected subgroups have improved outcomes relative to historical standards.
- Significant treatment gaps persist among patients without actionable mutations, despite recent advances in targeted therapies.
- Over the next 3-5 years, bispecific antibodies and antibody-drug conjugates are expected to drive another major therapeutic shift, although testing and toxicity management challenges persist.
- Platinum-based combination chemotherapy has long served as the backbone of systemic therapy for advanced or unresectable BTC across the 7MM.
- Pembrolizumab in combination with platinum-based chemotherapy is approved for locally advanced unresectable or metastatic BTC, establishing immunotherapy in the first-line setting.
- Durvalumab combined with gemcitabine and platinum chemotherapy is also an established first-line immunochemotherapy regimen for advanced BTC in major regulatory regions.
- Recent approvals have expanded targeted options: FGFR inhibitors (pemigatinib, futibatinib) for FGFR2-fusion-positive cholangiocarcinoma and IDH1 inhibitor ivosidenib for previously treated IDH1-mutated disease.
- Additional established targeted agents include PD-1/TIGIT, HER2, TROP2, DLL4, VEGF-A, and HER2/mEGFR-directed therapies.
- Emerging therapies such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), Tucatinib (TUKYSA) (Seagen/Pfizer), BOLD-100 (Bold Therapeutics), Silmitasertib (CX-4945) (Senhwa Biosciences), VG161 (Virogin Biotech), RP3-003 (Replimune), Sevabertinib (BAY 2927088) (Bayer), Opaganib (ABC294640) (RedHill Biopharma), Lirafugratinib (RLY-4008) (Relay Therapeutics/Elevar Therapeutics), Olomorasib (LY3537982) (Eli Lilly), CGT4859 (Cogent Biosciences), MT-4561 (Tanabe Pharma America), and others, continue to focus on pathway inhibition through novel inhibitors and antibodies, supporting more personalized treatment approaches beyond traditional chemotherapy.
Biliary Tract Cancer Competitive Landscape
Some of the BTC drugs in the clinical trial landscape include Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), Tucatinib (TUKYSA) (Seagen/Pfizer), BOLD-100 (Bold Therapeutics), Silmitasertib (CX-4945) (Senhwa Biosciences), VG161 (Virogin Biotech), RP3-003 (Replimune), Sevabertinib (BAY 2927088) (Bayer), Opaganib (ABC294640) (RedHill Biopharma), Lirafugratinib (RLY-4008) (Relay Therapeutics/Elevar Therapeutics), Olomorasib (LY3537982) (Eli Lilly), CGT4859 (Cogent Biosciences), MT-4561 (Tanabe Pharma America), and others.
TransThera Sciences’ Tinengotinib is an experimental oral multikinase inhibitor being evaluated for cholangiocarcinoma, with a particular focus on patients with FGFR alterations and disease progression after prior treatments. In contrast to first-generation selective FGFR inhibitors, it targets FGFR1-3, as well as VEGFRs, Aurora kinases, and JAK kinases, providing broader coverage of tumor growth, angiogenesis, and mechanisms of acquired resistance. The therapy is currently under investigation in a global Phase III study for cholangiocarcinoma.
AstraZeneca’s Rilvegostomig is a pioneering bispecific checkpoint inhibitor designed to simultaneously block PD-1 and TIGIT on the same immune effector cell, thereby reactivating antitumor immunity and enabling durable responses. Its TIGIT-targeting arm is derived from COM902, a fully owned antibody developed by Compugen, one of only two Fc-reduced anti-TIGIT antibodies in clinical development. Rilvegostomig is now being tested in several Phase III trials involving patients with BTC.
The anticipated launch of these emerging therapies are poised to transform the biliary tract cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the biliary tract cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the emerging BTC therapies and pipeline drugs @ Biliary Tract Cancer Drugs
Recent Developments in the Biliary Tract Cancer Market
- In December 2025, Compugen announced an agreement with AstraZeneca to monetize a portion of its future royalties from rilvegostomig. As part of this transaction, Compugen amended its exclusive license agreement with AstraZeneca, originally executed in March 2018, to strengthen its balance sheet and advance its differentiated immuno-oncology pipeline.
- In July 2025, Jazz Pharmaceuticals announced that the European Commission granted conditional marketing authorization for ZIIHERA as monotherapy for the treatment of adults with unresectable, locally advanced, or metastatic HER2-positive (IHC 3+) BTC who had received at least one prior line of systemic therapy.
- In April 2025, TransThera announced poster presentations at the 2025 AACR Annual Meeting to discuss clinical data on tinengotinib in patients with advanced solid tumors from a Phase Ib/II study.
What is Biliary Tract Cancer?
Biliary tract cancer is a rare but aggressive group of cancers that arises in the bile ducts, gallbladder, or ampulla of Vater, structures responsible for transporting bile from the liver to the small intestine. These cancers can block the normal flow of bile, leading to symptoms such as jaundice, abdominal pain, weight loss, and itching. Because early symptoms are often subtle, biliary tract cancer is frequently diagnosed at an advanced stage, making treatment more challenging. Management typically involves a combination of surgery, chemotherapy, radiation therapy, and, in some cases, targeted or immunotherapies.
Biliary Tract Cancer Epidemiology Segmentation
The biliary tract cancer epidemiology section provides insights into the historical and current biliary tract cancer patient pool and forecasted trends for the leading markets. In 2024, the majority of BTC patients in Japan were diagnosed at an advanced stage (77% of total cases), whereas early-stage disease accounted for the remaining 23%.
The biliary tract cancer treatment market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
- Total Incident Cases of BTC
- Tumor Site-specific Incident Cases of BTC
- Age-specific Incident Cases of BTC
- Stage-specific Incident Cases of BTC
- Mutation-specific Incident Cases of BTC
- Line-wise Treated Cases of BTC
Biliary Tract
Details
Cancer Market
Report Metrics
Study Period
2020-2034
Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom,
and Japan].
Biliary Tract 10.1 %
Cancer Market
CAGR
Biliary Tract
USD 1.1 Billion
Cancer Market
Size in 2024
Key Biliary Tract TransThera Sciences (HKG: 2617), AstraZeneca (LON: AZN), J-Pharma, OHARA Pharmaceutical
(TYO:
Cancer 5218), Compass Therapeutics (NASDAQ: CMPX), Merck (NYSE: MRK), Eisai (TYO: 4523), Seagen
(NASDAQ:
Companies SGEN), Pfizer (NYSE: PFE), Bold Therapeutics (NASDAQ: BOLD), Senhwa Biosciences, Virogin
Biotech,
Replimune (NASDAQ: REPL), Bayer (ETR: BAYN), RedHill Biopharma (NASDAQ: RDHL), Relay
Therapeutics
(NASDAQ: RLAY), Elevar Therapeutics, Eli Lilly (NYSE: LLY), Cogent Biosciences (Cogent
Biosciences),
Tanabe Pharma America (TYO: 4508), Incyte (NASDAQ: INCY), Roche (SWX: ROG), Genentech,
Loxo
Oncology (NASDAQ: LOXO), Jazz Pharmaceuticals (NASDAQ: JAZZ), Daiichi Sankyo (TYO: 4568),
and others
Key Biliary Tract Tinengotinib, Rilvegostomig, Nanvuranlat (JPH203), Tovecimig (CTX-009), Lenvatinib
mesylate
Cancer Therapies (LENVIMA), Tucatinib (TUKYSA), BOLD-100, Silmitasertib (CX-4945), VG161, RP3-003,
Sevabertinib (BAY
2927088), Opaganib (ABC294640), Lirafugratinib (RLY-4008), Olomorasib (LY3537982),
CGT4859, MT-
4561, PEMAZYRE, ROZLYTREK, VITRAKVI, ZIIHERA, ENHERTU, TASFYGO, and others
Scope of the
Biliary Tract Cancer
Market Report
- Therapeutic Assessment: Biliary Tract Cancer current marketed and emerging therapies
- Biliary Tract Cancer Market Dynamics: Key Market Forecast Assumptions of Emerging Biliary Tract Cancer Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Biliary Tract Cancer Market Access and Reimbursement
Download the report to understand the BTC therapy market share by company @ Biliary Tract Cancer Market Analysis
Table of Contents
1
Biliary Tract Cancer Market Key Insights
2
Biliary Tract Cancer Market Report Introduction
3
Executive Summary
4
Key Events
4.5
News Flow
5
Epidemiology and Market Forecast Methodology
6
BTC Market Overview at a Glance
7
Disease Background and Overview
7.1
Introduction
7.2
Classification of BTC
7.3
Staging
7.4
Signs and Symptoms
7.5
Causes and Risk Factors
7.6
Pathophysiology
7.7
Genetic Findings in BTC
7.8
Biomarkers
7.9
Diagnosis of BTC
7.10
Differential Diagnosis
7.11
Treatment
7.12
Diagnostic and Treatment Guidelines for BTC
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale
8.3
Total Incident Cases of BTC in the 7MM
8.4
The United States
8.4.1
Total Incident Cases of BTC in the United States
8.4.2
Tumor Location-specific of BTC in the United States
8.4.3
Age-specific Incident Cases of BTC in the United States
8.4.4
Stage-specific Incident Cases of BTC in the United States
8.4.5 Mutation-specific Incident Cases of BTC in the United States
8.4.6
Systemic inflammation in BTC in the United States
8.5
EU4 and the UK
8.6
Japan
9
Biliary Tract Cancer Patient Journey
10
Marketed Biliary Tract Cancer Therapies
10.1
Key Cross Competition
10.2
Pemigatinib (PEMAZYRE): Incyte
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Summary of Pivotal Trials
10.2.5
Analyst’s View
10.3
Entrectinib (ROZLYTREK): Roche/Genentech
10.4
Larotrectinib (VITRAKVI): Bayer/Loxo Oncology
10.5 Ivosidenib (TIBSOVO): Agios Pharmaceuticals/Servier Pharmaceuticals
10.6
Futibatinib (LYTGOBI): Taiho
10.7
Pembrolizumab (KEYTRUDA): Merck
10.8
Durvalumab (IMFINZI): AstraZeneca
10.9
Dabrafenib (TAFINLAR) + Trametinib (MEKINIST): Novartis
10.10
Selpercatinib (RETEVMO): Eli Lilly
10.11
Zanidatamab (ZIIHERA): Jazz Pharmaceuticals
10.12 Trastuzumab deruxtecan (ENHERTU): AstraZeneca and Daiichi Sankyo
10.13
Tasurgratinib (TASFYGO): Eisai
11
Emerging Biliary Tract Cancer Therapies
11.1
Key Cross Competition
11.2
Tinengotinib (TT-00420): TransThera Sciences
11.2.1
Product Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trial Information
11.2.4
Safety and Efficacy
11.2.5
Analyst Views
11.3
Rilvegostomig: AstraZeneca and Compugen
11.4
Nanvuranlat (JPH203): J-Pharma/OHARA Pharmaceutical
11.5
Tovecimig (CTX-009): Compass Therapeutics
11.6
Lenvatinib mesylate (LENVIMA): Merck and Eisai
11.7
Tucatinib (TUKYSA): Seagen/Pfizer
11.8
BOLD-100: Bold Therapeutics
11.1
VG161: Virogin Biotech
12
BTC Market: 7MM Analysis
12.1
Key Findings
12.2
Biliary Tract Cancer Market Outlook
12.3
Conjoint Analysis
12.4
Key Biliary Tract Cancer Market Forecast Assumptions
12.5
Total Market Size of BTC in the 7MM
12.6
Total Market Size of BTC by Therapies in the 7MM
12.7
The United States Biliary Tract Cancer Market
12.7.1
Total Market Size of BTC in the United States
12.7.2
Total Market Size of BTC by Therapies in the United States
12.8
EU4 and the UK Biliary Tract Cancer Market
12.9
Japan Biliary Tract Cancer Market
13
Biliary Tract Cancer Market Unmet Needs
14
Biliary Tract Cancer Market SWOT Analysis
15
KOL Views on BTC
16
Biliary Tract Cancer Market Access and Reimbursement
16.1
The United States
16.2
In EU4 and the UK
16.3
Japan
16.4 Summary and Comparison of Market Access and Pricing Policy
Developments in 2025
16.5
Market Access and Reimbursement of BTC Therapies
17
Bibliography
18
Biliary Tract Cancer Market Report Methodology
Related Reports
Biliary Tract Cancer Clinical Trial Analysis
Biliary Tract Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key BTC companies, including Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee’s Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee’s Pharmaceutical Limited, and others.
Cholangiocarcinoma Market
Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cholangiocarcinoma companies, including AstraZeneca, Decalth Systems, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharma, and others.
Liver Cancer Market
Liver Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key liver cancer companies, including Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, Bristol-Myers Squibb, and others.
Bile Duct Cancer Market
Bile Duct Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bile duct cancer companies, including AstraZeneca Plc., Bayer AG, Merck & Co Inc., Advenchen Laboratories LLC, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
+14699457679
www.delveinsight.com
Logo – https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biliary-tract-cancer-market-is-predicted-to-exhibit-remarkable-growth-at-a-cagr-of-10-1-during-the-forecast-period-20252034–delveinsight-302701330.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…